RPRX News
  • Repros Says Fully Enrolls Second Head To Head Study Of Androxal Versus Topical Testosterone Gel
    5/13/2014
  • Repros Therapeutics Q1 Loss/Shr $0.37 Vs. Loss $0.41 Last Year
    5/12/2014
  • Repros Therapeutics Received FDA Guidance Regarding Primary Endpoints For Two Studies, ZA-304 And ZA-305
    4/30/2014
  • Repros Receives FDA Guidance That It May Proceed To Conduct Phase 1 And 2 Studies Of Oral Proellex
    3/17/2014
  • Repros Therapeutics Announces Addl. Results From ZA-300 Six Month Study Of Androxal In Men With Secondary Hypogonadism
    2/10/2014

Next 10 Headlines